Omeprazol Medical Valley (Omeprazole)

Omeprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining.
• Peptic ulcer disease: supports ulcer healing by maintaining a higher gastric pH.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours.
• Erosive esophagitis: aids in mucosal repair and reduces further erosion.
• Helicobacter pylori eradication regimens (as adjunct): enhances the effectiveness of antibiotic combinations used to eradicate the bacterium.

• Omeprazole irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly reduces basal and stimulated gastric acidity, allowing the gastrointestinal mucosa to heal and decreasing reflux‑related symptoms.

Adverse reactions to omeprazole may range from mild to serious. The profile reflects the drug class and typical patient experience.

Common Side Effects

• Headache: mild, transient headache reported by some patients.
• Diarrhoea: loose stools occurring during early treatment.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach region.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, breathing difficulty.
• Clostridioides difficile infection: persistent diarrhoea with abdominal cramping.
• Low magnesium (hypomagnesemia): muscle cramps, irregular heartbeat.
• Bone fracture risk: increased incidence of hip, wrist or spine fractures with long‑term use.
• Liver enzyme elevation: abnormal liver function test results.
• Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

When prescribing omeprazole, clinicians should consider several safety aspects:

• Assess renal and hepatic function: dose adjustment may be needed in severe impairment.
• Review long‑term use: prolonged therapy is linked to nutrient malabsorption and fracture risk.
• Monitor for infections: increased susceptibility to gastrointestinal infections such as C. difficile.
• Evaluate pregnancy status: use only if the potential benefit outweighs the risk.
• Consider drug‑interaction potential: check concomitant medications for CYP2C19 substrates.
• Store at ambient temperature: keep below 25 °C, protect from moisture and retain in original packaging.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines. Awareness of the interaction level helps guide monitoring.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, increasing cardiovascular event risk.
• Atazanavir: markedly decreased antiviral exposure, compromising HIV therapy.
• Methotrexate (high dose): increased systemic exposure, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Warfarin: potential alteration of INR, requiring more frequent coagulation monitoring.
• Phenytoin: possible reduction in serum levels, may diminish seizure control.
• Digoxin: modest increase in serum concentration, monitor for signs of toxicity.